comprehensive -WSS

comprehensive

author：explore 2025-10-01 23:39:30 - browse：6426

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Despite FDA concern, risk that CAR

WSS

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

Cigna, Humana reportedly in talks to merge

U.K. Biobank has 500,000 peoples' genome sequences available

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Timeline: Special counsel's investigation into Trump's handling of classified documents

leisure time

comprehensive

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

GOP presidential candidates start declaring their loyalty

In Memoriam: Notable people who died in 2023

Will the market for weight loss drugs really reach $100 billion?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Despite FDA concern, risk that CAR

In age of alternative facts, a scholarly course on calling out crap

White House drug shortages task force keeps mum with Congress

As demand for Covid shots wanes, Moderna seeks its next success

Fetal surgery at risk from Dobbs and new abortion restrictions

entertainment

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

TB outbreak tied to bone grafts underscores testing shortcomings

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Disappointing trial forces Pfizer to pivot on obesity medicine plans

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Kim Kardashian sparks debate on benefits of full

knowledge

explore

knowledge

focus